mRNA Influenza Vaccine Description
Pfizer's mRNA-based influenza vaccine requires only the genetic sequence of the virus.
Utilizing this technology will provide the flexibility to match the actual circulating influenza strains. The traditional influenza vaccines are based on predictions for the future strains chosen more than six months before the start of the season.
The quadrivalent modRNA vaccine candidate will encode World Health Organization recommended strains for the Northern Hemisphere 2022-23 cell culture- or recombinant-based influenza vaccines.
mRNA Influenza indication
mRNA Influenza is indicated to confer protection against the circulating influenza strains.
mRNA Influenza Clinical Trials
Phase 3 Clinical Trial: A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
Phase 1/2 Clinical Trial: A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified RNA Vaccine Against Influenza